SCHEMBL3012037

SCHEMBL3012037

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
RECQL P46063 2/20 0.49
USP2 O75604 2/20 0.49
HSD17B10 Q99714 1/20 0.49
PKM P14618 7/20 0.48
PKLR P30613 3/20 0.48
LMNA P02545 5/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002772 0.93 MAPT (0.49) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3005922 0.91 MAPT (0.47) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3006376 0.89 MAPT (0.46) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3012668 0.88 MAPT (0.54) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3016403 0.87 MAPT (0.42) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3018783 0.87 MAPT (0.61) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3019600 0.87 MAPT (0.43) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3022377 0.87 MAPT (0.43) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3012535 0.86 MAPT (0.54) MAPTRECQLUSP2HSD17B10PKM
SCHEMBL3013082 0.86 ALDH1A1 (0.46) MAPTRECQLUSP2HSD17B10PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.